CELH vs CRSP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CELH and CRSP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CELH and CRSP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Celsius Holdings is a Boca Raton, Florida consumer packaged goods company that makes functional energy drinks marketed around fitness, metabolism, and zero-sugar formulations. Its flagship CELSIUS brand is sold through grocery, club, convenience, and fitness channels, and the company makes money by selling cases of ready-to-drink beverages, increasingly through PepsiCo's distribution network. In Q2 2026 the broader portfolio held roughly a 20.1% dollar share of the U.S. ready-to-drink energy category (down from about 20.9% in Q1), placing it behind Monster and Red Bull but well ahead of most other challengers.

Full CELH guide

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.

Full CRSP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CELH drivers: Multi-brand portfolio and category leadership; PepsiCo distribution and the category-captain role.
• CRSP drivers: First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The flagship CELSIUS brand slowed to roughly 6% growth in Q1 2026 and then shrank about 11.7% year over year in Q2 2026, so the portfolio's growth now rests on Alani Nu and Rockstar, and total revenue growth fell to about 10.6% once those brands entered the prior-year base. For CRSP, the commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $13.4 million over the twelve months to June 2026.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CELH if you believe its drivers more; CRSP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CELH and CRSP guides.

CELH. Reported figures are drawn from Celsius Holdings' Q2 2026 results and market data as of October 16, 2026. Trailing GAAP earnings are depressed by acquisition-related charges, so the trailing P/E near 125 times says little; on forward estimates the stock trades near 17 times earnings and about 2.4 times sales. Shares near $29 sit about 40% below where they started 2026 and well below the 52-week high of $66, a valuation that now reflects doubts about the core brand rather than the growth premium it once carried.

CRSP. Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based multiples like P/E are negative and not analytically useful; the company is better evaluated on cash runway, Casgevy adoption, and the risk-adjusted value of its pipeline. Market cap of about $4.9 billion less roughly $1.6 billion of net cash leaves an enterprise value near $3.3 billion, which reflects significant execution uncertainty. Targets remain widely spread, from UBS at $52 to a consensus mean near $86.

Headline figures (approximate, October 2026): CELH shows revenue (ttm) ~$3.05 billion, revenue (q2 2026) ~$817.9 million, up ~10.6% YoY, celsius brand revenue (q2 2026) Down ~11.7% YoY, gross margin (q2 2026) ~48.1% (down ~340 bps); CRSP shows revenue (ttm to jun 30, 2026) ~$13.4 million (Q2 2026 ~$10.2 million), revenue (full year 2025) ~$3.5 million, net loss (ttm) ~$451 million; Q2 2026 ~$91 million, eps (q2 2026, actual vs estimate) -$0.94 vs -$1.18.

CELH and CRSP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CELH and CRSP exposure against your real portfolio. It is not an investment adviser.